Zacks Research Has Strong Estimate for GSK FY2027 Earnings

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $5.05 per share for the year, up from their previous estimate of $5.04. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

A number of other equities analysts have also recently weighed in on the company. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.6 %

GSK opened at $38.54 on Thursday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK has a one year low of $31.72 and a one year high of $45.93. The firm has a market capitalization of $79.77 billion, a P/E ratio of 24.24, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The company has a fifty day moving average price of $37.11 and a 200-day moving average price of $36.82.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%.

Hedge Funds Weigh In On GSK

A number of hedge funds have recently modified their holdings of GSK. FMR LLC boosted its holdings in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the period. Clifford Capital Partners LLC boosted its stake in shares of GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after acquiring an additional 51,378 shares during the period. Stifel Financial Corp grew its position in shares of GSK by 9.7% during the third quarter. Stifel Financial Corp now owns 604,973 shares of the pharmaceutical company’s stock worth $24,731,000 after purchasing an additional 53,440 shares in the last quarter. Grimes & Company Inc. purchased a new stake in shares of GSK during the fourth quarter worth about $4,731,000. Finally, Strategic Financial Concepts LLC bought a new stake in GSK during the 4th quarter valued at approximately $4,033,000. 15.74% of the stock is currently owned by institutional investors.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.08%. GSK’s dividend payout ratio (DPR) is presently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.